Trinity Capital Inc. Stock Price, News & Analysis

Trinity Capital (Nasdaq: TRIN) announced a $15 million growth capital commitment to Kard on October 21, 2025 to accelerate expansion of Kard's commerce media network.

Kard powers merchant-funded, API-first rewards for banks, fintechs and loyalty programs, reaching tens of millions of consumers and processing over $10 billion in transactions each month. Trinity said the funding will help Kard scale operations and expand into new markets while Kard will continue using aggregated spend data and AI-driven personalization to drive incremental merchant growth and strengthen issuer loyalty.

Trinity Capital (Nasdaq: TRIN) committed $130 million in growth capital to Candel Therapeutics (Nasdaq: CADL) on October 14, 2025 to support development of viral immunotherapies.

The funding is earmarked to support clinical development of CAN-2409 and pre-commercial and launch readiness activities for CAN-2409 in prostate cancer pending regulatory approval. Candel's pipeline includes CAN-2409 and CAN-3110 targeting solid tumors (prostate, pancreatic, lung, brain).

Candel has received multiple FDA designations: RMAT for localized prostate cancer, Fast Track for localized prostate and non-small cell lung cancer, and dual Fast Track and Orphan Drug designations for pancreatic and brain cancer programs.

Trinity Capital (Nasdaq: TRIN) reported that it originated $773 million of new commitments in Q3 2025, bringing year-to-date new commitments to $1.5 billion through the first three quarters of 2025.

Q3 2025 investments funded totaled approximately $471 million (comprised of $381M secured loans, $57M equipment financings, $33M warrants/equity). Q3 proceeds from repayments and exits were ~$255 million. For the first three quarters, investments funded were ~$1.1 billion and proceeds totaled ~$607 million.

The company will release complete Q3 2025 financial results and host a conference call on November 5, 2025 at 12:00 p.m. ET.

Trinity Capital (Nasdaq: TRIN) appointed Paul D'Agrosa as Managing Director of Life Sciences, based in Denver, effective Oct. 8, 2025.

Mr. D'Agrosa joins to help expand Trinity's Life Sciences platform across new U.S. markets; he brings more than a decade of experience in loan origination, business development, and relationship management. His prior roles include Managing Director at Horizon Technology Finance, where he helped originate more than $140 million in new loan commitments within his first 15 months, and 10 years at Silicon Valley Bank in relationship and credit roles.

The company framed the hire as a step to strengthen life‑sciences lending and source new opportunities across Medtech, Healthtech, Biotech, and Diagnostics/Tools.

Trinity Capital (Nasdaq: TRIN) will report its third quarter 2025 financial results on Wednesday, November 5, 2025 at 8:00 a.m. ET.

The company will host a conference call the same day at 12:00 p.m. ET; participants may dial (800) 267-6316 or (203) 518-9783 internationally and reference Conference ID: TRINQ325. A taped replay will be available about two hours after the call and remain accessible until November 12, 2025 via (800) 753-9146 or (402) 220-2705. A live webcast and a 90-day on‑demand replay will be available on the company's investor relations website at ir.trinitycapital.com.

Trinity Capital (NASDAQ:TRIN) has committed $45 million in growth capital to Rapid Micro Biosystems (NASDAQ:RPID), a life sciences technology company specializing in automation solutions for microbial quality control in healthcare product manufacturing. The funding will support Rapid Micro's global expansion of their Growth Direct® platform and investments in manufacturing efficiency improvements.

The Growth Direct® platform enhances microbial testing processes by providing faster results, improved accuracy, increased operational efficiency, and enhanced data integrity. The capital will be used to scale operations, support commercial expansion, and drive gross margin growth through cost reduction and improved manufacturing efficiency.

AZ-VC has announced the launch of its second venture capital fund, AZ-VC II, following the success of its $115 million Fund I. Led by former PayPal executive Jack Selby, the fund focuses on non-coastal startups, targeting Series A investments in post-revenue companies with proven product-market fit.

The fund is backed by notable Arizona-based limited partners including Pinnacle West Corporation, Western Alliance Bancorp, Trinity Capital (NASDAQ: TRIN), and Salt River Project. AZ-VC's investment strategy capitalizes on an average 70% valuation discount compared to coastal companies with similar metrics, addressing the significant disparity where California, New York, and Massachusetts receive 75% of venture capital despite representing only 22% of the U.S. population.

Trinity Capital (NASDAQ: TRIN) has committed $100 million in growth capital to Angel Studios (NYSE: ANGX), a values-driven entertainment company. This investment follows Angel Studios' recent business combination with Southport Acquisition Corporation and subsequent listing on the NYSE.

Angel Studios operates with a unique model where its 1.5 million Angel Guild members worldwide participate in content selection, effectively acting as virtual co-producers for films and TV shows. The company distributes content through theaters, television, and its streaming platform, focusing on uplifting and values-based entertainment.

Trinity Capital (NASDAQ:TRIN), a leading alternative asset manager, has declared a quarterly cash dividend of $0.51 per share for Q3 2025. The dividend will be paid on October 15, 2025 to shareholders of record as of September 30, 2025.

This marks Trinity's 23rd consecutive quarter of maintaining or increasing its dividend, remaining consistent with the previous quarter's payout. The company aims to distribute 90-100% of its taxable quarterly income through four quarterly dividends to maintain its regulated investment company tax status.